Manufacturer's Perspective Jim Hayes

February 10, 2014

Agenda

Emerging Biosimilar Market

Defining "Biosimilars"

Path to Regulatory Approval

Experience in Europe

Emerging Market Dynamics in the US

Conclusions



Blockbuster biologics expected to go lose exclusivity in the next 5 years \rightarrow Avonex, Remicade, Lantus, Humira, and Avastin.




Expected biosimilar market size by $2020 \rightarrow US$, Japan, China, South Korea, and EU as the key source of business.



Manufacturers investing in biosimilar development, manufacturing and commercializing capabilities → Key players in US, Japan, China, South Korea, Germany and India.

Biosimilars represent a sizeable and growing opportunity



Source: Campbell Alliance Analysis, 2013, EvaluatePharma.

The definition of biosimilar varies



World Health Organization

A biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product¹



A biological medicine that is developed to be similar to an existing biological medicine (the 'reference medicine'). When approved, a Biosimilar's variability and any differences between it and its reference medicine will have been shown not to affect safety or effectiveness²



Biological product that is highly similar to a U.S. licensed reference biological product notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product³

^{1.} World Health Organization. Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). World Health Organization. [Online] October 23, 2009. [Cited: March 23, 2012.] http://www.who.int/biologicals/areas/biological_therapeutics/ BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.

European Medicines Agency. Questions and Answers on biosimilar medicines (similar medicinal products). European Medicines Agency. [Online] September 27, 2012. [Cited: October 1, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf. . EMA/837805/2011.

^{3.} U.S. Food and Drug Administration. Guidance for Industry: Quality considerations in demonstration biosimilarity to a reference protein product. Washington DC: U.S. Food and Drug Administration, 2012

Biosimilars are not the same as generics

Biosimilars

Similar, not the same as reference product

Biologics Price Competition and Innovation Act

Approval will be through preclinical and clinical trials

Anticipated cost differential 20-30%

Considerable manufacturing expertise required (development cost of \$30 to \$100M)

May have unique non-proprietary name

Trade secrets, IP, cell lines, and manufacturing/purification/packaging information about reference product is not readily available

Biosimilar designation ≠ interchangeable (TBD)

Generics

Bioequivalent to branded product

Hatch-Waxman Act

Approval with ANDA demonstration of bioequivalence

Cost differential can be as high as 90%


Manufacturing expertise not as complex (development cost of \$3M to \$5M)

Generics from various manufacturers all have single generic name

Easy to duplicate chemical formula of branded product; usually simple packaging


Generic = interchangeable

Even if biosimilar uses the same human gene as the originator, *different process = different product*




Source: Biologics manufacturing process. From Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:412–419; by permission of Oxford University Press.

In the US, extensive non-clinical and clinical evidence will likely be required for the relevant TA



Post-Approval

The EU market for biosimilars is significantly less restricted than the US market




Source: GBI Research Market Research Report. July 2012. EMA. www.ema.europa.eu/. Fiercebiotech. www.fiercebiotech.com/. Manufacturer Press Releases. Accessed October 2012.

The competitor-set is rapidly growing

	(Oncology Biosimilars			Inflammation Biosimilars			Other	Additional
	Hercepti n	Avastin	Rituxan	Erbitux	Humira	Remicade	Enbrel	Biosimilars	Information
AMGEN	х	X	x	x	x	X			
SANDOZ/ NOVARTIS			х				x	 Epoetin Filgrastim Omnitrope Pegfilgrastim 	Up to 7 biosimilars may be in developmen
PFIZER	x		x			x			Two additional biosimilars in development (not yet named)
TEVA			x					 Epoetin Filgrastim Pegfilgrastim Follitropin alfa 	Dissolved partnership with Lonza (Rituximab)
HOSPIRA/ CELLTRION	x		x			X		 Epoetin Filgrastim Pegfilgrastim 	Up to 11biosimilars may be in developmen
BOEHRINGER- INGELHEIM		X	х		х				
MERCK & CO/ SAMSUNG BIOEPIS		February 2013: reported they had entered into an agreement to develop a multiple of pre-specified but undisclosed biosimilar candidates (current status unknown)							
MERCK SERONO/ DR REDDY'S	,	June 2012: announced a partnership to co-develop a portfolio of biosimilar components in oncology, primarily focused on monoclonal antibodies							
BAXTER/ COHERUS AND							X (Coherus)		Three biosimilars in development with Momenta

Country-specific healthcare policies have had an impact on biosimilar adoption in the EU



Perceptions of biosimilars vary between US and EU physicians. Payers in both regions view biosimilars as a cost containment necessity

Physician Insights

- Physicians believe that **concerns about efficacy and safety** will be major factors in constraining the use of biosimilars but most expect to prescribe them within one year of launch.
- The majority of physicians agree that regulatory agencies should require manufacturers to **establish REMS programs** for both branded biologics and biosimilars.
- US physicians would be **most likely to prescribe "biobetter" drugs** that demonstrate improvements in efficacy, safety, or dosing.
- More European physicians than US physicians believe that biosimilars and branded biologics are very similar and have non-clinically significant differences.

Payer Insights

- **Payers view biosimilars as necessary to contain costs** and expect significant price discounts to incentivize uptake. EU payers anticipate branded price cuts to follow.
- Payers will likely **require more clinical information than what might be accepted by the FDA** for approval when evaluating biosimilar therapies due to concerns about efficacy and safety.
- Payers perceive large biotechnology companies as the most trustworthy when developing a biosimilar therapy.
- US payers expect **pharmacy-level substitution to be applied** to biosimilars within five years.

The "simple" biosimilars will focus on creating a commodity market

<i>Likely</i> Biosimilar Go-To-Market Approach	"Simple" Biosimilar (e.g., somatropin, filgrastim, epoetin alfa)
Market Segmentation / Customer Analysis	Focus on highly cost-sensitive markets, such as the hospital segments
Positioning & Messaging	 Develop corporate level confidence in safety, efficacy, and supply with all customers Message on simplicity of biologic structure and history of use in EU
Pricing & Contracting	Discount up to 20% with contracting for key segments
Field Force	Provide traditional sales and account management teams
Customer Support Services	Develop baseline level of customer support services
Lifecycle Management	۶

In this market, the originators will maintain their pricing strategy and compete with contracting and value-added support services

<i>Likely</i> Brand Competitive Response	"Simple" Biologic (e.g., somatropin, filgrastim, epoetin alfa)
Market Segmentation / Customer Analysis	 <i>Pre-launch:</i> Focus on cost-sensitive markets with contracting <i>Post-launch:</i> Focus on clinically focused/evidence based markets
Positioning & Messaging	 <i>Pre-launch:</i> Focus on safety and confidence of overall brand performance <i>Post-launch:</i> Focus on history and safety of brand
Pricing & Contracting	 <i>Pre-launch:</i> Contract with cost-sensitive market <i>Post-launch:</i> Maintain pricing strategy and contract for continued access
Field Force	 <i>Pre-launch:</i> Target account management activities <i>Post-launch:</i> Continue field support
Customer Support Services	Post-launch: Provide exceptional value added services and support
Lifecycle Management	Pursue lifecycle management opportunities in advance of LOE

The "complex" biosimilars will focus on creating trust and seek payer / regulatory support

<i>Likely</i> Biosimilar Go-To-Market Approach	"Complex" Biosimilar (e.g., monoclonal antibodies, botulinumtoxin, etc.)
Market Segmentation / Customer Analysis	Focus on highly controlled payer segments to direct use and physician segments focused on "cost recovery" model through buy and bill
Positioning & Messaging	 Develop corporate level confidence in safety, efficacy, and supply with all customers Target "interchangeability" and "extrapolation" of indications at approval
Pricing & Contracting	Discount less than 20% with contracting for key segments
Field Force	 Provide traditional sales and account management teams with focus on field reimbursement specialists
Customer Support Services	 Develop significant level of customer support services
Lifecycle Management	Investigate opportunities for development of "bio-betters"

In this market, the originators will focus heavily on safety messages lack of interchangeability

<i>Likely</i> Brand Competitive Response	"Complex" Biologic (e.g., monoclonal antibodies, botulinumtoxin, etc.)
Market Segmentation / Customer Analysis	 <i>Pre-launch:</i> Message all customers on safety <i>Post-launch:</i> Focus on clinically focused/evidence based markets
Positioning & Messaging	 <i>Pre-launch:</i> Focus on "non-interchangeability" and extrapolation of indications <i>Post-launch:</i> Focus on history and safety of brand
Pricing & Contracting	 <i>Pre-launch:</i> Contract with cost-sensitive payers <i>Post-launch:</i> Maintain pricing strategy and contract for continued access and volume discounts
Field Force	 <i>Pre-launch:</i> Target physician customers with messaging strategy <i>Post-launch:</i> Continue field support with focus on complexity of biologics
Customer Support Services	Post-launch: Provide exceptional value added services and support
Lifecycle Management	 Pursue lifecycle management opportunities in advance of LOE Focus on new administration devices and extended release formulations (in chronic therapeutic areas)

Conclusions

US Regulatory Approval	 Success or failure of biosimilars will be heavily dependent on FDA determination of interchangeability designation, as well as on the extrapolation of indications at approval
Commercialization	 Biosimilars should be considered similar to branded biologics in that traditional commercialization strategies and tactics will be required for success
Pricing & Contracting	 Unlike in the EU market, biosimilars are not expected to enter the market at significant pricing discounts to originators given the marketing spends that will be required for success
Uptake	• Overall biosimilar use will likely be slow and require significant time in the market to develop the confidence needed to drive utilizaiton